CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 20,702 enrolled
Drug / intervention
Enalapril/folic acid +1 moredrug
Likely dose
Enalapril/folic acid 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00794885
NCT00794885Phase 4Completed
CompareCT.gov

Enalapril Maleate and Folic Acid Tablets for Primary Prevention of Stroke in Patients With Hypertension: a Post-marketing, Double-blind, Randomized Controlled Trial.

Shenzhen Ausa Pharmed Co.,Ltd·interventional·Posted Nov 20, 2008·Updated Aug 12, 2014

In Brief

A Phase 4 clinical trial evaluating Enalapril/folic acid and Enalapril maleate for Primary Hypertension. Completed, enrolled 20,702 participants across 2 sites.

Detailed Summary

The purpose of this trial is to confirm that enalapril maleate and folic acid tablets is more effective in preventing stroke among the patients with primary hypertension when compared to enalapril maleate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hypertension
CountriesChina
CollaboratorsAnhui Medical University

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 20, 2008
Enrollment StartMay 1, 2008
Primary CompletionAug 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 17.6 years ago

Interventions

Enalapril/folic aciddrug

Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.

Enalapril maleatedrug

Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.